Version history

{
  "session_id": "sess_SDA-2026-04-23-gap-debate-20260417-033119-54941818_task_9aae8fc5",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"Therapeutic Window Exists Because Amplified Signals (Not Baseline) Drive Pathogenesis (H3)\",\n      \"description\": \"G2019S basal RAB10 phosphorylation elevation may be secondary; true pathogenic driver is amplified stress-response signaling. Partial LRRK2 inhibition sufficient to normalize stress-induced spikes while preserving necessary baseline functions. LRRK2 knockout mice viability supports non-essential baseline hypothesis. Age-dependent neurodegeneration in knock-in mice suggests stress-dependent pathology rather than chronic baseline elevation.\",\n      \"target_gene\": \"LRRK2\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.78,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.88,\n        \"therapeutic_potential\": 0.92,\n        \"mechanistic_plausibility\": 0.74,\n        \"druggability\": 0.88,\n        \"safety_profile\": 0.75,\n        \"competitive_landscape\": 0.72,\n        \"data_availability\": 0.82,\n        \"reproducibility\": 0.75\n      },\n      \"composite_score\": 0.78,\n      \"evidence_for\": [\n        {\"claim\": \"LRRK2 knockout mice are viable, suggesting baseline function is non-essential\", \"pmid\": \"18687812\"},\n        {\"claim\": \"G2019S knock-in mice show age-dependent neurodegeneration only under stress\", \"pmid\": \"31694915\"},\n        {\"claim\": \"LRRK2 kinase inhibitors protect models at sub-maximal doses\", \"pmid\": \"33106311\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Lung foamy macrophage findings suggest safety may require complete inhibition\", \"pmid\": \"35241464\"},\n        {\"claim\": \"Age-dependent phenotype does not prove stress-dependence\", \"pmid\": \"31694915\"}\n      ]\n    },\n    {\n      \"title\": \"G2019S Acts as Lysosomal Volume-Sensing Amplifier via Enhanced RAB29-Dependent Recruitment (H1)\",\n      \"description\": \"G2019S specifically hyperactivates LRRK2 when recruited to swelling lysosomes via RAB29, creating pathogenic positive feedback where membrane stress increases RAB10 phosphorylation more than wild-type. Key experimental prediction: rise kinetics (slope) should differ between G2019S and WT, not merely baseline offset. RAB29 pathogenic mutations (PARK23) confirm disease relevance of this axis.\",\n      \"target_gene\": \"LRRK2,RAB29\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.72,\n        \"novelty\": 0.78,\n        \"feasibility\": 0.82,\n        \"therapeutic_potential\": 0.85,\n        \"mechanistic_plausibility\": 0.68,\n        \"druggability\": 0.70,\n        \"safety_profile\": 0.72,\n        \"competitive_landscape\": 0.65,\n        \"data_availability\": 0.68,\n        \"reproducibility\": 0.70\n      },\n      \"composite_score\": 0.73,\n      \"evidence_for\": [\n        {\"claim\": \"RAB29 pathogenic mutations (PARK23) cause early-onset Parkinsonism\", \"pmid\": \"28165311\"},\n        {\"claim\": \"RAB29 recruits LRRK2 to stressed lysosomes via GTP-dependent mechanism\", \"pmid\": \"30635564\"},\n        {\"claim\": \"G2019S shows selectively elevated RAB10 phosphorylation at lysosomes\", \"pmid\": \"33448356\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Recruitment enhancement of G2019S relative to WT not directly demonstrated\", \"pmid\": \"31511666\"},\n        {\"claim\": \"Positive feedback loop mechanism not shown\", \"pmid\": \"30635564\"}\n      ]\n    },\n    {\n      \"title\": \"RAB29 Is the Critical Molecular Switch That Determines Whether LRRK2 Signal Amplification Occurs (H4)\",\n      \"description\": \"RAB29 functions as a gatekeeper—when lysosomes swell, RAB29-GTP increases, recruits LRRK2, and G2019S hyperphosphorylates RAB10 disproportionately. The amplification is RAB29-dependent. Strategic pivot: RAB29 serves as predictive biomarker rather than drug target. RAB29 knockout in G2019S patient-derived neurons would determine if amplification requires RAB29.\",\n      \"target_gene\": \"RAB29\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.70,\n        \"novelty\": 0.82,\n        \"feasibility\": 0.78,\n        \"therapeutic_potential\": 0.80,\n        \"mechanistic_plausibility\": 0.72,\n        \"druggability\": 0.52,\n        \"safety_profile\": 0.78,\n        \"competitive_landscape\": 0.72,\n        \"data_availability\": 0.62,\n        \"reproducibility\": 0.68\n      },\n      \"composite_score\": 0.71,\n      \"evidence_for\": [\n        {\"claim\": \"RAB29 localizes to swollen lysosomes\", \"pmid\": \"30635564\"},\n        {\"claim\": \"RAB29 activates LRRK2 in cells\", \"pmid\": \"28067317\"},\n        {\"claim\": \"RAB29 knockout rescues LRRK2 pathogenic phenotypes in zebrafish\", \"pmid\": \"31743699\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Zebrafish data may not translate to mammalian neurons\", \"pmid\": \"31743699\"},\n        {\"claim\": \"RAB29 mutations cause disease through LRRK2 activation—switch model unclear\", \"pmid\": \"28165311\"}\n      ]\n    },\n    {\n      \"title\": \"LRRK2 G2019S Uncouples RAB29-Dependent Spatial Control from Kinase Activity (H7)\",\n      \"description\": \"Normally RAB29 recruits LRRK2 specifically to stressed lysosomes for localized RAB10 phosphorylation. G2019S increases kinase activity even in cytosolic/untargeted LRRK2, creating diffuse RAB10 phosphorylation that disrupts normal endosomal trafficking. RAB29 overexpression rescuing G2019S phenotypes suggests spatial control not completely uncoupled.\",\n      \"target_gene\": \"LRRK2,RAB29\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.85,\n        \"feasibility\": 0.58,\n        \"therapeutic_potential\": 0.68,\n        \"mechanistic_plausibility\": 0.65,\n        \"druggability\": 0.45,\n        \"safety_profile\": 0.62,\n        \"competitive_landscape\": 0.78,\n        \"data_availability\": 0.55,\n        \"reproducibility\": 0.62\n      },\n      \"composite_score\": 0.64,\n      \"evidence_for\": [\n        {\"claim\": \"LRRK2:RAB29 cryo-EM structure shows specific binding interface\", \"pmid\": \"34519112\"},\n        {\"claim\": \"RAB29 overexpression rescues G2019S phenotypes\", \"pmid\": \"30635564\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"R1078 is in WD40 domain, not RAB29 interface—mutation may confound results\", \"pmid\": \"34519112\"},\n        {\"claim\": \"If truly uncoupled, RAB29 overexpression would not rescue\", \"pmid\": \"30635564\"}\n      ]\n    },\n    {\n      \"title\": \"Baseline Elevation from ER Stress Is Epiphenomenon, Not Lysosomal Signal Amplification (H6)\",\n      \"description\": \"G2019S causes elevated baseline RAB10 phosphorylation via chronic ER stress pathway (PERK/eIF2α) unrelated to lysosomal volume-sensing. True signal amplification is pathogenic; baseline elevation is compensatory. PERK inhibitor GSK2606414 can test whether baseline elevation depends on ER stress in both genotypes.\",\n      \"target_gene\": \"PERK,LRRK2\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.52,\n        \"novelty\": 0.60,\n        \"feasibility\": 0.72,\n        \"therapeutic_potential\": 0.58,\n        \"mechanistic_plausibility\": 0.48,\n        \"druggability\": 0.62,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.65,\n        \"data_availability\": 0.58,\n        \"reproducibility\": 0.58\n      },\n      \"composite_score\": 0.59,\n      \"evidence_for\": [\n        {\"claim\": \"LRRK2 G2019S induces ER stress in dopaminergic neurons\", \"pmid\": \"28804131\"},\n        {\"claim\": \"PERK activation affects LRRK2 S935 dephosphorylation\", \"pmid\": \"28666988\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"PERK activation causes S935 dephosphorylation predicting lower activity, not elevated RAB10-p\", \"pmid\": \"28666988\"},\n        {\"claim\": \"ER stress is non-specific—would elevate LRRK2 in WT as well\", \"pmid\": \"28666988\"}\n      ]\n    },\n    {\n      \"title\": \"Dual-Mechanism Model: G2019S Increases Both Baseline AND Signal-Dependent Phosphorylation (H2)\",\n      \"description\": \"G2019S has two separable effects: (1) increases catalytic efficiency at baseline (higher floor), AND (2) increases LRRK2 membrane affinity upon lysosomal stress, amplifying volume-sensing signals. These may be pharmacologically separable. Membrane-association mutants could distinguish these mechanisms.\",\n      \"target_gene\": \"LRRK2\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.58,\n        \"feasibility\": 0.48,\n        \"therapeutic_potential\": 0.65,\n        \"mechanistic_plausibility\": 0.50,\n        \"druggability\": 0.42,\n        \"safety_profile\": 0.60,\n        \"competitive_landscape\": 0.68,\n        \"data_availability\": 0.52,\n        \"reproducibility\": 0.52\n      },\n      \"composite_score\": 0.55,\n      \"evidence_for\": [\n        {\"claim\": \"Cryo-EM structures show G2019S widens the activation segment\", \"pmid\": \"31511666\"},\n        {\"claim\": \"G2019S increases both cytosolic and membrane-bound LRRK2 activity\", \"pmid\": \"34242571\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Activation segment widening affects catalytic function, not membrane affinity\", \"pmid\": \"31511666\"},\n        {\"claim\": \"Membrane-association mutants may disrupt other interactions\", \"pmid\": \"34242571\"}\n      ]\n    },\n    {\n      \"title\": \"G2019S Amplifies Lysosomal Volume-Sensing Through Membrane Microdomain Partitioning (H5)\",\n      \"description\": \"G2019S increases LRRK2 affinity for negatively charged, curved membranes (PI4P-enriched lysosomal membranes during swelling). This is not a kinase catalytic change but a localization change that amplifies local RAB10 phosphorylation. dSTORM microscopy can quantify membrane density differences between G2019S and WT.\",\n      \"target_gene\": \"LRRK2,PI4P\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.45,\n        \"novelty\": 0.68,\n        \"feasibility\": 0.70,\n        \"therapeutic_potential\": 0.52,\n        \"mechanistic_plausibility\": 0.40,\n        \"druggability\": 0.48,\n        \"safety_profile\": 0.58,\n        \"competitive_landscape\": 0.72,\n        \"data_availability\": 0.52,\n        \"reproducibility\": 0.50\n      },\n      \"composite_score\": 0.56,\n      \"evidence_for\": [\n        {\"claim\": \"LRRK2 membrane localization requires PI4P\", \"pmid\": \"35189339\"},\n        {\"claim\": \"Lysosomal swelling increases PI4P on limiting membrane\", \"pmid\": \"34242571\"},\n        {\"claim\": \"G2019S accelerates LRRK2 autophosphorylation on S1292 (membrane-associated site)\", \"pmid\": \"25485852\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"G2019S is in kinase domain—structural mechanism for membrane affinity change unexplained\", \"pmid\": \"31511666\"},\n        {\"claim\": \"S1292 evidence is indirect marker of membrane association, not direct mechanism\", \"pmid\": \"25485852\"}\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"LRRK2\", \"target_type\": \"gene\", \"relation\": \"mutation causes gain-of-function at lysosomes\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"RAB29\", \"target_type\": \"gene\", \"relation\": \"recruits hyperactive LRRK2 to stressed lysosomes\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"RAB10\", \"target_type\": \"gene\", \"relation\": \"hyperphosphorylated downstream substrate\"},\n    {\"source_id\": \"H2\", \"source_type\": \"hypothesis\", \"target_id\": \"LRRK2\", \"target_type\": \"gene\", \"relation\": \"dual catalytic and membrane-affinity effects\"},\n    {\"source_id\": \"H3\", \"source_type\": \"hypothesis\", \"target_id\": \"LRRK2\", \"target_type\": \"gene\", \"relation\": \"partial inhibition therapeutic strategy\"},\n    {\"source_id\": \"H4\", \"source_type\": \"hypothesis\", \"target_id\": \"RAB29\", \"target_type\": \"gene\", \"relation\": \"critical gatekeeper for amplification\"},\n    {\"source_id\": \"H4\", \"source_type\": \"hypothesis\", \"target_id\": \"LRRK2\", \"target_type\": \"gene\", \"relation\": \"amplified signaling requires RAB29 presence\"},\n    {\"source_id\": \"H5\", \"source_type\": \"hypothesis\", \"target_id\": \"LRRK2\", \"target_type\": \"gene\", \"relation\": \"altered membrane partitioning mechanism\"},\n    {\"source_id\": \"H5\", \"source_type\": \"hypothesis\", \"target_id\": \"PI4P\", \"target_type\": \"lipid\", \"relation\": \"increased affinity during swelling\"},\n    {\"source_id\": \"H6\", \"source_type\": \"hypothesis\", \"target_id\": \"PERK\", \"target_type\": \"kinase\", \"relation\": \"ER stress upstream of baseline elevation\"},\n    {\"source_id\": \"H6\", \"source_type\": \"hypothesis\", \"target_id\": \"LRRK2\", \"target_type\": \"gene\", \"relation\": \"elevated baseline from ER stress\"},\n    {\"source_id\": \"H7\", \"source_type\": \"hypothesis\", \"target_id\": \"LRRK2\", \"target_type\": \"gene\", \"relation\": \"uncoupled from RAB29 spatial control\"},\n    {\"source_id\": \"H7\", \"source_type\": \"hypothesis\", \"target_id\": \"RAB29\", \"target_type\": \"gene\", \"relation\": \"binding interface preserved but not functionally coupled\"}\n  ],\n  \"synthesis_summary\": \"The debate reveals that the signal amplification vs. baseline elevation distinction carries profound therapeutic implications: if amplification drives pathology (H3), partial LRRK2 inhibition preserves safety margins while normalizing pathogenic stress responses; if baseline elevation alone is pathogenic, complete inhibition becomes necessary. Current clinical trials (Denali DNL151/BIIB122, Pfizer) are implicitly testing the H3 model but lack mechanistic biomarker stratification to distinguish outcome predictions. The prioritized experimental pathway is: (1) live-cell kinetic imaging (H1) to definitively distinguish amplification from floor effects using fluorescent RAB10 phosphorylation reporters and nigericin-induced swelling—identical rise slopes with baseline offset falsify amplification; (2) CRISPR RAB29 knockout in G2019S iPSC-derived neurons (H4) to determine if amplification requires RAB29, with RAB29 expression as a potential companion diagnostic; (3) embedded mechanistic biomarker studies in ongoing Phase II trials measuring both steady-state and ex-vivo stress-elicited RAB10-p. The membrane partitioning hypothesis (H5) is mechanistically weakest because G2019S resides in the kinase domain, not membrane-targeting regions, and the ER stress hypothesis (H6) fails to explain G2019S specificity given PERK's dephosphorylation effect would predict lower, not higher, activity.\"\n}\n```",
  "tokens_used": "3497",
  "persona_id": "persona-synthesizer"
}